52
Participants
Start Date
March 28, 2017
Primary Completion Date
March 1, 2024
Study Completion Date
March 1, 2024
Matched targeted drug treatment
Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
Unmatched standard of care
"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
Cedars-Sinai Medical Center, Los Angeles
Cedars-Sinai Medical Center
OTHER